Autophagy is central to aging biology, but proving target engagement and clinical benefit in humans remains difficult. The piece keeps the focus on evidence, commercial logic, and what would make the claim testable.
A measured piece on mTOR, off-label enthusiasm, human evidence, side effects, dosing, and why rapamycin remains both important and unresolved. The piece keeps the focus on evidence, commercial logic, and what would make the claim testable.
Treat reprogramming as the next major therapeutic frontier, but frame the real product as control, delivery, reversibility, and safety rather than simple rejuvenation. The piece keeps the focus on evidence, commercial logic, and what would make the claim testable.
Few ideas in longevity science remain as intuitively powerful as senolytics. If aging tissues accumulate senescent cells — damaged cells
Few drug classes have moved from endocrinology into so many neighboring territories so quickly. What began as a diabetes story